[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"assisted-reproductive-technology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:assisted-reproductive-technology":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,82,111,147,175,202,226,272,307,331,358],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100640272","effectiveness-of-live-motile-sperm-sorting-device-on-ivf-outcomes-in-advanced-paternal-age-100640272",false,"NCT07605182","Effectiveness of Live Motile Sperm Sorting Device on IVF Outcomes in Advanced Paternal Age","Evaluation of the Effectiveness of Live Motile Sperm Sorting Device on In Vitro Fertilization Outcomes in Advanced Paternal Age Group","IVF","Inclusion Criteria:\n\n* Male partners aged ≥ 40 years\n* Semen analysis: volume ≥ 1.4 mL, sperm concentration ≥ 6 million\u002FmL, progressive motility (PR) ≥ 20% after 3-5 days of abstinence.\n* Female partners with ≥ 5 mature (MII) oocytes retrieved.\n* Couples undergoing ICSI with PGT-A and elective single embryo transfer (eSET).\n* Willingness to participate and sign informed consent.\n\nExclusion Criteria:\n\n* Azoospermia, surgical sperm retrieval, or use of cryopreserved sperm.\n* Female uterine or ovarian conditions severely affecting IVF outcomes.\n* Use of donor sperm or donor oocytes","ALL","40 Years",{"count":20,"type":21},378,"ESTIMATED","INTERVENTIONAL",[24],"NA","Male infertility contributes significantly to infertility, particularly in advanced paternal age men where sperm DNA fragmentation is increased. Conventional density gradient centrifugation may induce oxidative stress and sperm damage. LensHooke® CA0 is a centrifugation-free sperm sorting device designed to improve sperm quality and reduce DNA fragmentation. This prospective comparative study evaluates the effectiveness of CA0 versus conventional density gradient centrifugation on post-processing sperm quality, DNA fragmentation index, blastocyst formation, euploid embryo rate, and clinical pregnancy outcomes in IVF\u002FICSI cycles involving men aged 40 years or older",[27,28,29],"Male Infertility","Advanced Paternal Age","Assisted Reproductive Technology",[31,32,33,34],"DNA fragmentation","Advanced paternal age","ICSI","LensHooke CA0","NOT_YET_RECRUITING","2026-05-19",{"date":38,"type":39},"2026-05-22","ACTUAL",{"date":41,"type":21},"2026-05-05",{"date":43,"type":21},"2027-12-30",{"name":45,"class":46},"Vietnam Military Medical University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100606285","st-marys-assisted-reproductive-technology-and-cardiometabolic-health-modifiable-targets-for-multimorbidity-prevention-start-healthy-100606285","NCT07173569","St Mary's Assisted Reproductive Technology and Cardiometabolic Health: Modifiable Targets for Multimorbidity Prevention (START-HEALThY)","START-HEALThY","Inclusion Criteria:\n\n* In pre-conception cohort:\n\n  * Aged between 16 and 45\n  * Able to provide informed consent\n  * Either: 1) Those with a history of infertility (failure to conceive after at least 1 year of unprotected intercourse\u002F3-6 cycles of Intra-Uterine Insemination (IUI) or diagnosed cause of infertility) and accepted for IVF at The Department of Reproductive Medicine, MFT or, 2) attending for a pre-conception appointment at MFT\n  * Nulliparous (no previous pregnancies beyond 20 weeks)\n  * No pre-existing heart disease, hypertensive disease, vascular disease or diabetes\n* In post-pregnancy cohort\n\n  * Aged between 16 and 45\n  * Able to provide informed consent\n  * Participant of START clinic study (achieved pregnancy via a) IVF with or without ICSI treatment, b) spontaneous conception without medical intervention within 12 months, or c) spontaneous conception following ovulation induction for delay in spontaneous conception \\>12 months or confirmed anovulation)\n\nExclusion Criteria:\n\n\\- In all participants:\n\n* Prisoners\n* Born male at birth\n* Language barrier not overcome by telephone or video interpretation services\n* Pregnant at time of study visit\n\nPre-conception participants only:\n\n• Accepted for IVF for non-infertility reasons i.e. egg donation, egg collection, egg banking, gestational surrogacy",true,"FEMALE","16 Years","45 Years",{"count":60,"type":21},120,"OBSERVATIONAL","The main causes of death in women are conditions affecting the heart and blood vessels (cardiovascular disease, CVD). Women who have difficulties getting pregnant (infertility) may be at increased risk, but the reasons for this are not clear. Infertility itself may be linked with poorer heart and blood vessel health, or fertility treatments such as in vitro fertilisation (IVF) could increase the risk.\n\nThe study aims to understand the practicalities of obtaining detailed profiling of women's pre- and post- pregnancy heart, blood vessel and metabolic health. Two groups of women in Manchester University NHS Foundation Trust, will be recruited over 2 years: 1) women planning a pregnancy, either spontaneously or with IVF treatment after infertility, 2) women who previously took part in a pregnancy health study after IVF or non-IVF conception.\n\nParticipants will attend a single research appointment where they will undergo a cardiometabolic health assessment. They will have their BMI calculated, body composition measured, a measurement of how well their blood vessels work using a blood pressure cuff around the arm and\u002For finger and blood sampling performed. A blood pressure cuff as well as a blood sugar sensor may be fitted to be worn after the appointment. Participants will be asked to complete a questionnaire(s), with follow-up for up to 13 months.\n\nThe cardiometabolic health of those who conceived with or without IVF treatment and with or without a history of infertility will be compared at both time points to investigate the possibility of links between infertility, IVF processes and CVD risk and to understand any potential barriers to recruitment of individuals at either time point to guide future studies. This information could then be used in a full-scale study, including in pregnancy, to improve care and promote lifelong health for women with infertility.",[64,65,29,66,67,68],"Maternal Cardiometabolic Health","Infertility","Cardiovascular Health","Metabolic Health","in Vitro Fertilisation",[70,71,72],"Feasibility study","Ambulatory cardiometabolic health monitoring","Cohort","2026-04-27",{"date":75,"type":39},"2026-04-28",{"date":77,"type":21},"2026-05-01",{"date":79,"type":21},"2028-10-31",{"name":81,"class":46},"University of Manchester",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":56,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":47},"100534418","validation-of-donor-oocytes-semi-automated-vitrification-100534418","NCT06238570","Validation of Donor Oocytes Semi-automated Vitrification","Validation of Semi-automatic Oocyte Vitrification by the GAVI® Machine in Medically Assisted Reproduction With Oocyte Donation","GAVIDO","Inclusion Criteria:\n\n* Egg donor\n* Oocyte puncture for donation\n* Good quality ovarian reserve (Antral follicle count evaluated by ultrasound: CFA ≥ 7)\n* Negative serology status (HIV, hepatitis B and C, syphilis, CMV and HTLV)\n* Absence of symptoms or COVID contact\n* Absence of genetic contraindication to egg donation\n* Woman able to give informed consent to participate in research\n* Woman affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Decline to participate\n* Pregnant and lactating woman\n* Person under guardianship, curatorship, deprivation of liberty, protection of justice","18 Years","38 Years",{"count":93,"type":21},50,[24],"Oocyte vitrification is an effective method of freezing which has been authorized in France since 2011. The arrival of this technique has led to real improvements in the survival rate of oocytes after warming compared to that observed after slow freezing, a method previously applied. Oocytes reheated after vitrification show excellent results in terms of vitality and recovery of cellular functionality. Indeed, the fertilization rates observed after using warmed and fertilized oocytes in Assisted Reproduction Technology (ART) by intracytoplasmic sperm injection (ICSI) are similar to those obtained with fresh oocytes.\n\nHowever, the manual vitrification techniques used until now involve a learning curve and a potential variability of the completion time depending on the operator and the number of oocytes to be vitrified.\n\nOocyte vitrification is a key step to optimize the chances of pregnancy in ART after using these oocytes. However, manual vitrification requires a learning curve, is technician-dependent and requires significant technical time.\n\nA semi-automatic vitrification device (GAVI®, Merck), which recently appeared on the market, has demonstrated its effectiveness in terms of speed of production and reproducibility of vitrification of embryos obtained in ART. To our knowledge, no study has analyzed the effectiveness of semi-automatic vitrification (GAVI®, Merck) on survival and oocyte quality after warming. It would therefore be interesting to evaluate the effectiveness of this automaton on oocyte vitrification in the context of oocyte donation and to determine the impact of semi-automatic vitrification on oocytes compared to manual vitrification.\n\nThe main objective of this study is to demonstrate the non-inferiority of vitrification semi-automated device (Gavi) of oocytes with regard to the oocyte survival rate, compared to the manual technique used in ART.\n\nThe investigator will compare the effectiveness of semi-automated vitrification device with the manual technique, in terms of ART results by comparing the fertilization rates, the number and quality of embryos obtained as well as the implantation rates in oocyte recipient patients. This study will then allow clinical application of the most efficient protocol for oocyte vitrification in the context of oocyte donation. A cost\u002Feffectiveness study will be carried out.",[97,98,99,29],"Vitrification","Egg Donor","Fertility",[99,101,97,29],"Egg donor","RECRUITING",{"date":104,"type":39},"2026-04-30",{"date":106,"type":39},"2024-01-23",{"date":108,"type":21},"2026-12",{"name":110,"class":46},"University Hospital, Clermont-Ferrand",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":56,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":122,"conditions":123,"keywords":130,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100634727","decision-aid-for-elective-egg-freezing-100634727","NCT07543445","Decision Aid for Elective Egg Freezing","Knowledge, Decision-making, and Oocyte Cryopreservation Outcomes in Taiwanese Women Considering Elective Egg Freezing: a Randomized Controlled Trial","DAEEF","Inclusion Criteria:\n\n* Women aged 20 years or older.\n* Currently considering elective egg freezing (EEF).\n* Able to communicate and read Chinese fluently.\n* Have access to the internet and a mobile device (smartphone, tablet, or computer) to complete online questionnaires.\n\nExclusion Criteria:\n\n* Individuals who have previously completed oocyte cryopreservation.\n* Women undergoing fertility preservation due to malignancy (i.e., breast cancer).\n* Postmenopausal women.","20 Years",{"count":60,"type":21},[24],"The goal of this clinical trial is to evaluate whether a culturally tailored decision aid can improve decision-making and clinical outcomes for Taiwanese women considering elective egg freezing.\n\nThe main questions it aims to answer are:\n\nDoes the decision aid improve women's knowledge about elective egg freezing and help clarify their personal values? Does the decision aid reduce decision regret and psychological distress after making a decision about egg freezing?\n\nResearchers will compare women who use the decision aid with those who receive standard counseling to see if the tool improves knowledge, reduces distress and regret, and leads to better clinical outcomes (such as completing egg freezing or achieving a higher number of frozen oocytes).\n\nParticipants will:\n\n* Complete questionnaires assessing their baseline knowledge, attitudes, and values regarding egg freezing\n* Receive either the decision aid or standard counseling\n* Complete follow-up questionnaires to assess knowledge, distress, and decision regret\n* Have their clinical outcomes recorded, including whether they undergo egg freezing and the number of oocytes retrieved and frozen",[124,125,126,127,128,29,129],"Elective Egg Freezing","Oocyte Cryopreservation","Decision Aid","Egg Freezing","Shared Decision Making","Fertility Preservation",[131,132,133,134,135,136,137],"elective egg freezing","planned oocyte cryopreservation","fertility preservation","decision aid","shared decision making","assisted reproductive technology","randomized controlled trial","2026-04-15",{"date":140,"type":39},"2026-04-21",{"date":142,"type":21},"2026-04-13",{"date":144,"type":21},"2031-12-31",{"name":146,"class":46},"National Taiwan University Hospital",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":55,"sex":17,"minAge":90,"maxAge":18,"enrollmentInfo":155,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100633895","microbiome-and-metabolome-profiles-in-couples-undergoing-ivf-and-reproductive-outcomes-100633895","NCT07532629","Microbiome and Metabolome Profiles in Couples Undergoing IVF and Reproductive Outcomes","Microbiome and Metabolome Profiles in Couples Undergoing IVF and Their Association With Reproductive Outcomes in a Prospective Longitudinal Cohort Study","Mi IVF","Inclusion Criteria:\n\n* Women aged 18 to 40 years at enrolment.\n* Men aged between 18 to 56 years at enrolment.\n* Couples planning to undergo IVF treatment at a participating centre.\n* Sufficient understanding of spoken and written Swedish or English to provide informed consent and complete the web-based questionnaire.\n\nExclusion Criteria:\n\n* Pregnancy at the time of enrolment (confirmed or suspected).\n* Recent systemic antibiotic use within the past 4 weeks\n* Active vaginal or genital tract infection at the time of sampling",{"count":156,"type":21},1000,"This prospective observational cohort study investigates the role of the microbiome and metabolome in couples undergoing in vitro fertilization. Biological samples will be collected from both female and male partners, including semen, vaginal, and blood samples, to characterize microbial composition and metabolic profiles. The study aims to examine how these biological profiles are associated with reproductive outcomes such as fertilization, pregnancy, miscarriage, and live birth. Participants will be followed longitudinally, and reproductive and obstetric outcomes will be obtained through linkage with national health registers.",[65,29,159,160,161,162],"Pregnancy Complications","Pregnancy Loss, Early","Metabolome","Microbiome",[15,162,161,164,165],"Male fertility","Pregnancy outcome",{"date":167,"type":39},"2026-04-16",{"date":169,"type":39},"2022-06-10",{"date":171,"type":21},"2029-03-01",{"name":173,"class":46},"Karolinska Institutet",3,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":55,"sex":56,"minAge":90,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":191,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":47},"100628363","gamified-healthy-lifestyle-training-in-women-undergoing-assisted-reproductive-treatment-100628363","NCT07460661","Gamified Healthy Lifestyle Training in Women Undergoing Assisted Reproductive Treatment","The Effect of Gamified Healthy Lifestyle Behavior Training on Healthy Lifestyle and Self-Efficacy in Women Undergoing Assisted Reproductive Treatment","Inclusion Criteria:\n\n* Women aged 18-49 years\n* Diagnosed with primary infertility\n* Currently undergoing assisted reproductive treatment (IUI, IVF, or ICSI)\n* Able to read, understand, and communicate in Turkish\n* Have access to a digital device (mobile phone, tablet, or computer) and internet connection\n* Provide voluntary written informed consent\n\nExclusion Criteria:\n\n* Diagnosed psychiatric disorder that may interfere with participation\n* Presence of a severe medical condition (e.g., active cancer or other serious systemic disease) that may affect treatment outcomes\n* Medical complications requiring hospitalization during the study period\n* Communication barriers preventing completion of study procedures\n* Withdrawal of consent at any time during the study","49 Years",{"count":184,"type":21},105,[24],"Objective: A prospective randomized controlled trial with a pretest-posttest design was planned to evaluate the effects of a gamified healthy lifestyle behaviors training intervention using the D6 model, to be administered to women undergoing assisted reproductive treatment (ART), on healthy lifestyle behaviors and infertility self-efficacy.\n\nAim: Reproductive health and Assisted Reproductive Technologies (ART) have undergone rapid technological and clinical development in recent years, offering a variety of treatment options to couples struggling with infertility. Methods such as Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), and Intracytoplasmic Sperm Injection (ICSI) are the most common practices aimed at increasing pregnancy rates. However, these treatments are complex processes affected by high stress levels, emotional burden, and lifestyle factors. Strengthening individuals' sense of self-efficacy strengthens their motivation to adapt to treatment and achieve health-related goals. In this intense and complex treatment process, it is essential to strengthen the self-efficacy perceptions of infertile couples, as this can enhance their motivation to achieve health-related goals by improving their adaptation to the treatment process. Although the literature reveals findings indicating that the development of healthy lifestyle behaviors positively influences the treatment outcomes of individuals undergoing infertility treatment, it is an undeniable fact that developing and sustaining such behaviors is often challenging-even for healthy individuals. For those experiencing infertility, which represents a complex life crisis both psychologically and physiologically, this process can become even more difficult. In this context, gamification is intended to be utilized as an innovative approach by integrating it into the process of promoting healthy lifestyle behaviors among infertile women.\n\nMethod: This study will be a prospective randomized controlled trial with a pretest-posttest model. The study population will consist of women undergoing assisted reproductive treatment who presented to the In Vitro Fertilization Unit in the Infertility and Reproductive Endocrinology Department at Istanbul University, Istanbul Faculty of Medicine Service Building, between October 2025 and October 2026. The sample will consist of 105 infertile women who met the study criteria based on a power analysis and agreed to participate in the study. After obtaining informed consent from infertile women who meet the study criteria and agree to participate, the women will be randomly assigned to three groups based on age, type of ART (IUI, IVF, ICSI), and number of treatments to ensure equality between the groups. These groups will be divided into three groups: a group receiving gamified healthy lifestyle behaviors education and a booklet during the ART process, a group receiving only the booklet, and a group receiving standard ART clinic training. All study groups will complete an Introductory Information Form, the Healthy Lifestyle Behavior Follow-up Form for Infertile Women, the Healthy Lifestyle Behavior Scale II (HLBS II), and the Infertility Self-Efficacy Scale Short Form (SES). One group will receive the gamified healthy lifestyle behaviors education program and a booklet, while the second group will receive the healthy lifestyle behaviors education booklet. The third group will receive standard ART clinic training. Post-tests (Healthy Lifestyle Behaviors for Infertile Women Follow-up Form, Healthy Lifestyle Behaviors Scale II, Infertility Self-Efficacy Scale Short Form) and \"Gamified Healthy Lifestyle Behaviors Training Program Evaluation Form\" was given to the group receiving gamified healthy lifestyle behaviors training will be administered to all groups at the end of Month 1. Repeat tests (Healthy Lifestyle Behaviors for Infertile Women Follow-up Form, Healthy Lifestyle Behaviors Scale II, Infertility Self-Efficacy Scale Short Form, and Gamified Healthy Lifestyle Behaviors Education Program Evaluation Form) will be administered at Month 3.\n\nAs part of the study, the effects of gamified healthy lifestyle behaviors and self-efficacy on the healthy lifestyle behaviors and self-efficacy of infertile women who received gamified healthy lifestyle behaviors education and an educational booklet during the ART process will be compared with those of infertile women who received only the educational booklet, compared to those who received standard ART clinic training. This will scientifically demonstrate the contribution of the gamification approach to the behavioral change processes of infertile women.",[188,65,29,189,190],"Infertility in Women Undergoing Assisted Reproductive Treatment","Health Lifestyle Behaviors","Self-Efficacy",[192],"Assisted Reproductive Treatment, Infertility, Healthy Lifestyle, Gamification, Self-Efficacy","2026-03-06",{"date":195,"type":39},"2026-03-10",{"date":197,"type":21},"2026-03-01",{"date":199,"type":21},"2027-03-01",{"name":201,"class":46},"Marmara University",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":55,"sex":17,"minAge":90,"maxAge":209,"enrollmentInfo":210,"targetDuration":212,"studyType":61,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":47},"100622519","environmental-and-behavioral-factors-in-infertility-and-art-outcomes-100622519","NCT07384676","Environmental and Behavioral Factors in Infertility and ART Outcomes","A Large-Scale Prospective Cohort Study on the Association of Environmental Exposures and Behavioral Factors With Infertility and Assisted Reproductive Technology (ART) Success Rates","Inclusion Criteria:\n\n* A. Women aged 18 to 46 who use their own eggs; Men aged 18 to 55 who use their own sperm; B. Patients meeting the diagnostic criteria for infertility; C. Medical history clearly indicating the duration of persistent infertility; D. Voluntarily participating in the project and signing the informed consent form;\n\nExclusion Criteria:\n\n* A. The groups of artificial insemination patients with any of the following ARTs contraindications: a. The female has a sperm-egg combination disorder caused by tubal factors. b. The female has acute infections of the reproductive and urinary systems or sexually transmitted diseases. c. The female has genetic diseases, severe physical illnesses, or mental and psychological disorders. d. There is a history of giving birth to infants with congenital defects and it has been confirmed that the defect was caused by the female. e. The female has been exposed to teratogenic doses of radiation, toxins, or drugs and is in the active period. f. The female has bad habits such as alcoholism or drug abuse. B. The groups of first-generation and second-generation IVF patients with any of the following ARTs contraindications: a. Either of the parties providing gametes has acute infections of the reproductive and urinary systems and sexually transmitted diseases or has bad habits such as alcoholism or drug abuse. b. Either of the parties providing gametes has been exposed to teratogenic doses of radiation, toxins, or drugs and is in the active period. c. The female partner of the recipient who provides eggs or embryos has acute infections of the reproductive and urinary systems and sexually transmitted diseases, or has bad habits such as alcoholism or drug abuse. d. The female has an unviable uterus or severe physical illnesses that cannot withstand pregnancy. C. No embryo transfer was performed after egg retrieval; D. More than 180 days have passed since egg retrieval and frozen embryo transfer was performed.","46 Years",{"count":211,"type":21},5000,"18 Months","This large-scale study aims to understand how everyday environment and lifestyle may affect the success of fertility treatments like IVF. The main idea is that exposure to certain environmental chemicals (e.g., from plastics or air pollution) and personal habits (e.g., diet, stress) could be linked to whether these treatments result in a successful pregnancy and live birth.\n\nThe study will follow approximately 5,000 couples undergoing fertility treatment in Hunan, China. Participants will answer questionnaires about their health, lifestyle, and environment and provide small biological samples (like blood and urine) during their standard treatment process. Their treatment outcomes will be tracked anonymously.The goal is to identify factors that might lower the chances of treatment success. This knowledge could help future patients and doctors make informed decisions and could guide public health advice on reducing potential risks. The study has received ethical approval, and all participant information will be kept strictly confidential.",[215,29,216],"Environmental Exposure","Prospective Study","2026-01-26",{"date":219,"type":39},"2026-02-03",{"date":221,"type":39},"2024-12-01",{"date":223,"type":21},"2034-12-31",{"name":225,"class":46},"The Third Xiangya Hospital of Central South University",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":90,"maxAge":233,"enrollmentInfo":234,"targetDuration":236,"studyType":61,"phases":4,"briefSummary":237,"conditions":238,"keywords":250,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":47},"100616933","long-term-evaluation-of-fertility-preservation-options-in-women-in-cancer-remission-or-haematological-pathology-100616933","NCT07312058","Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology","FERT-ISSUES","Inclusion Criteria:\n\n* Women\n* Aged between 18 and 47 years\n* Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment\n* Having undergone a medical fertility preservation consultation\n* Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine\n* Currently in remission\n* Having expressed non-opposition to participation in the study\n\nExclusion Criteria:\n\n* Absence of remission\n* Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)\n* Decline to participate in the study","47 Years",{"count":235,"type":21},102,"1 Day","Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.\n\nWomen of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.\n\nHowever, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.\n\nThis project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.\n\nThis work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).\n\nIts objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.\n\nThis work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.",[129,239,240,241,242,243,29,244,245,246,247,248,249],"Cancer Remission","Reproductive Outcomes","Reproductive Health","Oncology","Fertility Counseling","Psychological Impact","Fertility Observatory","Patient Follow-up","Female Cancer Survivors","Fertility Preservation Techniques","Live Birth Rate",[251,252,253,254,242,255,256,257,258,259,260,261,262],"Fertility preservation","Cancer remission","Reproductive outcomes","Reproductive health","Fertility counseling","Assisted reproductive technology","Psychological impact","Fertility observatory","Patient follow-up","Female cancer survivors","Fertility preservation techniques","Live birth rate","2026-01-15",{"date":265,"type":39},"2026-01-16",{"date":267,"type":21},"2025-12-17",{"date":269,"type":21},"2027-01",{"name":271,"class":46},"Centre Hospitalier Universitaire, Amiens",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":56,"minAge":90,"maxAge":58,"enrollmentInfo":280,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100612720","levothyroxine-treatment-and-ivf-outcomes-in-women-with-subclinical-hypothyroidism-a-target-trial-emulation-100612720","NCT07257250","Levothyroxine Treatment and IVF Outcomes in Women With Subclinical Hypothyroidism: A Target Trial Emulation","Effectiveness of Levothyroxine Treatment on In Vitro Fertilization and Pregnancy Outcome in Women With Subclinical Hypothyroidism and Infertility: A Target Trial Emulation","LESI","Inclusion Criteria:\n\n* Women aged 18-45 years.\n* Diagnosed with subclinical hypothyroidism (TSH 4.2-\\\u003C10 mIU\u002FL with FT4 0.92-1.68 ng\u002FdL).\n* Undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) followed by frozen embryo transfer (FET).\n\nExclusion Criteria:\n\n* Overt hypothyroidism (TSH ≥10 mIU\u002FL and FT4 ≤0.92 ng\u002FdL).\n* Current or recent (within 1 month) use of drugs affecting thyroid function (levothyroxine, amiodarone, methimazole, propylthiouracil).",{"count":281,"type":21},900,"Subclinical hypothyroidism (SCH) is defined by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (fT4) levels. It affects approximately 5-7% of women of reproductive age and may negatively influence outcomes of assisted reproductive technology (ART). During controlled ovarian stimulation, rising estradiol increases thyroxine-binding globulin and thyroid hormone requirements. These physiological changes, combined with increased metabolic demand in early pregnancy, may worsen SCH and contribute to adverse outcomes such as miscarriage, preterm birth, and hypertensive disorders of pregnancy.\n\nAlthough levothyroxine (LT4) is routinely used to treat overt hypothyroidism, evidence for its benefit in SCH, especially among infertile women undergoing In Vitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI) with frozen embryo transfer (FET), remains inconclusive. Some trials and meta-analyses have shown reductions in miscarriage and neonatal mortality, while others have found no improvement in ART or obstetric outcomes.\n\nThis study aims to evaluate the effectiveness of levothyroxine therapy on IVF\u002FFET outcomes and subsequent pregnancy results in women with subclinical hypothyroidism and infertility. This retrospective cohort study will emulate the target trial to evaluate whether LT4 treatment, titrated to achieve a pre-transfer TSH \\\u003C 2.5 mIU\u002FL, improves implantation, live birth, and obstetric outcomes compared with expectant management.",[284,65,29,285,286,287],"Subclinical Hypothyroidism","In Vitro Fertilization (IVF)","Intracytoplasmic Sperm Injection","Frozen Embryo Transfer (FET)",[289,284,65,290,15,33,291,292,29,293,294,295,296],"Levothyroxine","Thyroid Disorders","Frozen Embryo Transfer","FET","Live Birth","Miscarriage","Pregnancy Outcomes","Thyroid Autoimmunity","2026-01-13",{"date":299,"type":39},"2026-01-14",{"date":301,"type":39},"2019-01-01",{"date":303,"type":21},"2026-03-30",{"name":305,"class":46},"Mỹ Đức Hospital",2,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":56,"minAge":90,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":316,"briefSummary":317,"conditions":318,"keywords":319,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":47},"100575337","family-foundations-for-individuals-pregnant-via-art-100575337","NCT06770972","Family Foundations for Individuals Pregnant Via ART","Family Foundations for Individuals Pregnant Via Assisted Reproductive Technology","Inclusion Criteria:\n\n1. Pregnant individuals via ART, at least 18 years of age\n2. Have a caregiving partner (e.g. spouse, grandparent; nanny; friend) who will attend sessions\n3. Provision of signed and dated informed consent form\n4. Stated willingness to comply with all study procedures and availability for the duration of the study\n5. English speaking\n\n7\\. Access to and familiarity with a tablet, smartphone, or computer\n\nExclusion Criteria:\n\n1. Psychosis\n2. Perinatal loss (current) - history of loss is OK\n3. Individuals outside of the US\n4. Do not have smartphones, tablets, computers (the FF class is virtual)",{"count":315,"type":21},40,[24],"The purpose of this study is to help expectant mothers build a coparenting bond and improve communication with a support person (co-caregiver). Participation will include completing two online surveys (one at 12-30 weeks gestation \\& one at 3 months postpartum), providing two at-home bloodspot collections and returning the collections via mail. Studies suggest that stress increases inflammation. Investigators aim to explore this by collecting a small amount of blood at the first and last session. Participants will also attend 9 virtual one-two hour Family Foundations (FF) intervention sessions (at no cost to participants) with a supportive co-caregiver. Total time commitment will be 18 hours, max, over a 6 month period.",[29],[29,320,321],"mental health outcomes","pregnancy","2025-12-18",{"date":324,"type":39},"2025-12-24",{"date":326,"type":39},"2025-06-11",{"date":328,"type":21},"2028-01-30",{"name":330,"class":46},"Cedars-Sinai Medical Center",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":56,"minAge":338,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":344,"conditions":345,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":47},"100592227","phase-2-effect-of-salidroside-on-pregnancy-outcomes-in-high-childbearing-age-patients-in-viro-fertilization-100592227","NCT06990685","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization","Effect of Salidroside on Pregnancy Outcomes in High Childbearing Age Patients in Viro Fertilization: an Open-label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥35 and \\\u003C 40 years old\n2. For the first or second cycle of IVF, ICSI or IVF with donor sperm\n3. According to the 2016 Poseton criteria for poor prognosis: the number of oocytes obtained in the previous routine ovulation induction protocol was 1-9, or AFC \\\u003C 5 or AMH \\\u003C 1.2ng\u002Fml (measured within the past half year) in both ovaries.\n\nExclusion Criteria:\n\n1. Patients with coagulation disorders\n2. Patients with previous abnormal uterine bleeding\n3. Combined with hydrosalpinx confirmed by B-ultrasound and HSG\n4. Uterine malformation (unicornuate uterus, septate uterus) or history of intrauterine adhesions\n5. Patients with previous spontaneous abortion ≥3 times\n6. Patients with contraindications to assisted reproductive technology or pregnancy\n7. Previous or current oral medication containing salidroside\n8. The controlled ovarian stimulation protocol included PPOS protocol, luteal phase ovulation induction protocol, and continuous stimulation protocol","35 Years","39 Years",{"count":341,"type":21},370,[343],"PHASE2","With the decreasing of birth rate and population in our country, population problem has become a long-term and strategic problem. In addition to the decrease in the number of women of childbearing age and the impact of unmarried women, the increase in the incidence of reproductive disorders and the delay of marriage and childbearing are also important factors leading to the continuous decline of the birth population in China. Among them, ovarian aging is a key factor causing female fertility difficulties. Therefore, establishing an effective prevention and treatment strategy for ovarian aging is of great significance for improving female reproductive health and serving the national population strategy. Recently, several supplements have been found to promote folliculogenesis and improve oocyte quality. However, to date, there is no approved therapeutic agent for the treatment of ovarian aging. Therefore, it is urgent to develop effective strategies for the prevention and treatment of ovarian aging.\n\nSalidroside is the main active component of Chinese medicine Rhodiola, and its content is highest in the root of rhodiola, which is also the main medicinal part. The main efficacy of salidroside in traditional Chinese medicine is to benefit qi, promote blood circulation, unblock pulse and relieve asthma. At the same time, in basic research, more and more experiments have shown that salidroside has a variety of pharmacological properties, including anti-hypoxia, anti-fatigue and anti-aging effects, anti-cancer, anti-inflammatory, anti-oxidation, antiviral and so on. These pharmacological effects suggest that salidroside may be an effective drug for the prevention and treatment of atherosclerosis, Parkinson's disease, Alzheimer's disease, pneumonia and other diseases. In terms of aging, it has been confirmed that salidroside supplementation can prolong the life span of pseudogill oryzias zhan and rescue premature aging of human skin fibroblasts, etc., which further confirms.\n\nThe aim of this study is to investigate the efficacy of salidroside as an adjuvant drug in improving the pregnancy outcomes of fresh embryo transfer in high childbearing age patients with poor ovarian response by comparing the pregnancy outcomes of fresh embryo transfer between salidroside group and blank control group. This pragmatic clinical study is expected to improve pregnancy outcomes of fresh embryo transfer cycles in women of advanced childbearing age with poor ovarian response.",[346,347,348,29],"Salidroside","Randomized Controlled Trial","In Vitro Fertilization","2025-05-22",{"date":351,"type":39},"2025-05-25",{"date":353,"type":21},"2025-06-01",{"date":355,"type":21},"2027-12",{"name":357,"class":46},"The Second Hospital of Shandong University",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":55,"sex":56,"minAge":119,"maxAge":18,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":47},"100562158","phase-1-a-comparing-study-between-sj04-and-ovidrel-in-healthy-subjects-100562158","NCT06599528","A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects","A Phase I Clinical Trial to Compare the Pharmacokinetics, Safety and Immunogenicity of SJ04 and Ovidrel® in Healthy Female Subjects in China","Inclusion Criteria:\n\n1. Healthy female subjects aged 20 to 40 years old (including boundary values).\n2. Weight not less than 45.0 kg, body mass index within the range of 19.0\\~26.0 kg\u002Fm2 (including boundary values).\n3. Menstrual cycle regularity, or menstrual regularity before taking oral contraceptives (25-34 days, including boundary values).\n4. The levels of follicle stimulating hormone(FSH), luteinizing hormone(LH), prolactin (PRL), estradiol (E2), progesterone (P), and testosterone (T) detected within 2-3 days after the last menstrual period before the first administration are within normal ranges or considered abnormal by the researchers to have no clinical significance.\n5. LH levels \\<5 IU\u002FL, FSH levels \\<4 IU\u002FL at Day -1.\n\nExclusion Criteria:\n\n1. Allergy or suspected allergy to any component of the experimental drug, control drug, GnRH, GnRH analogs used in this study.\n2. Use of any LH preparation, human menopausal gonadotropin (hMG) or human chorionic gonadotropin (hCG) preparation within 3 months prior to screening.\n3. Previously or currently suffering from the following diseases: hypothalamic or pituitary tumors, unexplained ovarian enlargement or cyst, Abnormal uterine bleeding of unknown etiology, malignant tumors of the ovaries, uterus, or breast, active thromboembolic diseases, uncontrollable thyroid or adrenal dysfunction, endocrine disorders such as hyperprolactinemia, polycystic ovary syndrome, ovarian hyperstimulation syndrome (OHSS), and ovarian dysfunction, other malignant tumors or diseases of the hypothalamus, pituitary gland, ovaries, and uterus (excluding uterine fibroids).\n4. Ectopic pregnancy within 3 months prior to screening.\n5. Presence of clinically significant acute or chronic infection at screening or enrolment。\n6. Presence of localised disease affecting the hypodermic site, or inability to tolerate hypodermic injections。\n7. Difficulty in blood collection or inability to tolerate venipuncture, or history of needle or blood sickness.\n8. Prescription medications taken within 14 days or 5 half-lives prior to screening or over-the-counter medications (including proprietary and herbal medications) taken within 7 days or 5 half-lives prior to screening .\n9. A history of chronic or serious illness or disease of the liver, kidneys, gastrointestinal tract, endocrine system, cardiovascular, neurological, metabolic, haematological, respiratory, or autoimmune systems or an existing disease of one of the above systems which, in the judgement of the investigator, makes him or her unsuitable for enrolment.\n10. Abnormalities in vital signs, physical examination, laboratory tests (routine blood, blood biochemistry, urinalysis, coagulation, thyroid function), 12-lead electrocardiogram, liquid-based thin-layer cytometry (TCT), and ultrasound are judged by the investigator to be clinically significant and to warrant participation in the trial.\n11. Positive tests for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and syphilis spirochete antibody.\n12. History of mental illness, substance abuse, drug dependence, or positive substance abuse screen (morphine, THC, methamphetamine, MDMA, ketamine) on the day of admission.\n13. Excessive consumption of tea, coffee or caffeinated beverages in the 3 months prior to screening.\n14. Drinking an average of more than 14 standard units of alcohol per week in the three months prior to screening, or inability to abstain from alcohol during the test period, or a positive breathalyser test result on the day of admission.\n15. Smoke at least 5 cigarettes per day in the 3 months prior to screening or not be able to stop using any tobacco-based products during the trial.\n16. Participated in a clinical trial of another drug within 28 days prior to screening and used the test drug, or participated in a clinical trial of a medical device within 1 month prior to screening.\n17. History of blood donation or bleeding \\>400 ml within 3 months prior to screening.\n18. During pregnancy or breastfeeding, or a positive pregnancy test result. The subject (or his\u002Fher partner) is planning to have children (including sperm and egg donation) throughout the trial period and for 3 months after the end of the trial. Unwilling to use one or more non-pharmacological contraceptive methods (e.g. total abstinence, condoms, ligation, etc.) during the trial period.\n19. Subjects who withdrew from the trial for their own reasons and who, in the opinion of the investigator, were otherwise unsuitable to participate in the trial.",{"count":366,"type":21},48,[368],"PHASE1","This is a single-centre, randomised, open-label, single-dose, two-cycle, double-crossover study to compare the pharmacokinetics of SJ04 and Ovidrel® in healthy female subjects. Received a single subcutaneous injection administration of SJ04 Injection or Ovidrel®, both administered at a dose of 250 μg, once per cycle, and cross-administered after a washout period.",[29,371],"Female Infertility","2025-02-05",{"date":374,"type":39},"2025-02-10",{"date":376,"type":39},"2024-08-12",{"date":378,"type":21},"2026-12-31",{"name":380,"class":381},"Suzhou Centergene Pharmaceuticals Co.,Ltd.","INDUSTRY"]